Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.
To examine the independent associations of prolonged and interrupted sedentary behavior with cancer risk among UK Biobank participants.
Approach:
Study Design: A prospective cohort study involving 91,292 participants without a history of cancer, using wrist-worn accelerometers to measure sedentary behavior and physical activity.
Data Collection: Participants wore accelerometers for 7 days between 2013 and 2015, with follow-up for a median of 12.4 years using hospital admission and mortality records.
Data Analysis: Multivariable Cox proportional hazards models were used, adjusting for various factors, and isotemporal substitution models estimated associations with replacing prolonged sedentary behavior.
Key Findings:
Prolonged sedentary behavior was linked to higher risks of cancer mortality and incidence, including obesity-related and type 2 diabetes-related cancers.
Interrupted sedentary behavior was associated with lower risks of cancer outcomes.
Each additional hour of prolonged sedentary behavior increased cancer mortality and incidence risks.
Replacing prolonged sedentary behavior with physical activity reduced cancer risks, especially with vigorous-intensity activity.
Interpretation:
Accumulating sedentary time in shorter, interrupted bouts is independently linked to a lower risk of cancer outcomes.
Limitations:
The study cannot prove causality.
Residual confounding and healthy volunteer bias may affect results.
Measurement imprecision due to only 7 days of accelerometer wear.
The accelerometer could not identify the context of sedentary activities.
Conclusion:
Replacing prolonged sedentary behavior with physical activity is associated with a lower risk of cancer death.
Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.
Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.
